CROs offering Ligand-Binding Bioanalysis (Large Molecule) with Gene Therapy
17 published
17 published CROs match Ligand-Binding Bioanalysis (Large Molecule) and Gene Therapy.
Locations in this set include United States, China, United Kingdom, India, Italy, and Mexico.
Capabilities that show up most often in this set: Bioanalysis, LC-MS Bioanalysis (Small Molecule), Biomarker Assays, Regulatory Affairs, and Biostatistics & Statistical Programming.
Matching companies
AltasciencesMid-size early phase CRO/CDMO in Canada and the U.S. offering preclinical safety testing, clinical pharmacology (Phase I–II), bioanalysis, research services, and manufacturing with integrated capabilities.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
CelerionGlobal CRO specializing in early-phase clinical research and bioanalytical sciences with 650+ beds across 30 countries and 50+ years of experience.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
Frontage LaboratoriesGlobal pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
ICON plcICON is a global clinical research organization providing full-service drug development and clinical trial solutions across early phase through post-marketing, including clinical operations, bioanalytical labs, cardiac safety, medical imaging, and regulatory affairs.
LabcorpLabcorp is a global life sciences and healthcare company providing diagnostic testing, drug development, nonclinical research, central laboratory services, and real-world data solutions to healthcare providers, health systems, and biopharma companies.
MedpaceFull-service CRO with 30+ years of organic growth, offering integrated clinical development services across all phases with wholly-owned central labs, bioanalytical lab, imaging core lab, and Phase I unit.
NorthEast BioLabBioanalytical CRO providing PK/PD, immunogenicity (ADA/nAb), cytokine, and biomarker assays across LC-MS, Meso Scale Discovery, ELISA, and ddPCR platforms. Operates GLP/GCLP-compliant facilities and reports DEA and CT approval for Schedule I–IV bioanalysis.
PPDPPD is a leading global contract research organization (CRO) and the clinical research business of Thermo Fisher Scientific.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
ProtheragenSpecialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.
SannovaSannova provides bioanalytical and analytical CRO services, including immunogenicity and ligand binding assays, PK testing, DMPK services, extractables and leachables, nitrosamine testing, and pharmaceutical stability testing. Its listed work spans small molecules, biologics and biosimilars, and cell and gene therapies.- Swiss BioQuant AGBioanalytical CRO offering LC-MS/MS and ligand-binding assay development, validation, and sample analysis for small and large molecules. Work runs in a 21 CFR Part 11 compliant environment, with qPCR support for gene therapy bioanalysis.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/ligand-binding-bioanalysis/gene-therapy.md